A Drug That May Be Better Than Marijuana Sent This Company's Stock Soaring 196% in September
Shares of Zogenix, Inc. (NASDAQ: ZGNX) skyrocketed 196% higher in September after the company reported data from a study that suggested low-dose fenfluramine lowers the rate of seizures in Dravet syndrome patients by more than GW Pharmaceuticals' (NASDAQ: GWPH) marijuana-based drug Epidiolex.
Zogenix's ZX008 may soon offer new hope to patients living with a rare form of epilepsy called Dravet syndrome.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
